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*Escherichia coli* is widely used for the production of recombinant polypeptides, including therapeutic proteins ([@B1]). The most popular system for protein overexpression in *E. coli* is the isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase cascade system, in which expression of the gene of interest is controlled by a T7 RNA polymerase promoter (e.g., on a pET vector) in a strain carrying the T7 RNA polymerase gene under control of an IPTG-inducible promoter (e.g., λDE3 lysogenic strains) ([@B2]). The genome sequence of the widely used *E. coli* B strain BL21(DE3) ([@B2]) is available ([@B3]). BLR(DE3) is a *recA*-deficient derivative of BL21(DE3) that helps stabilize plasmids containing repetitive sequences ([@B4]). According to Novagen, BLR(DE3) has the same genotype, except for a mutation in *recA* \[Δ(*srl*-*recA*)306::Tn*10*\], which was initially obtained in an *E. coli* K-12 background ([@B5]) and later transferred to BL21 ([@B4], [@B6]).

We sequenced the BLR(DE3) strain obtained from Novagen in order to verify whether additional differences are present in BLR(DE3) compared to BL21(DE3). We performed *de novo* hybrid assembly from PacBio sequencing (102,708 reads, with a mean length of 5,173 bp) and Illumina HiSeq 2000 sequencing (approx. 4,500,000 high-quality paired-end 100-bp reads) for closing gaps and correcting PacBio sequencing errors. A total of 4,306 coding sequences (CDSs), 230 pseudogenes, 85 tRNA genes, 22 rRNA genes (8 operons), and 64 noncoding RNA genes were annotated.

A comparison with BL21(DE3) indicates larger differences than expected, with two main divergent regions. First, the DE3 prophage contains three large deletions of 4.9 kb (*cro*-*Rz*), 1.8 kb (*A-B*), and 11.1 kb (*Fi*-*J*), suggesting the prophage is nonfunctional. As expected, the second divergent region is the *recA* locus. A 6.9-kb region from *recA* to *srlR* is replaced with Tn*10* in BLR(DE3). Besides *recA* and the *srl* operon, BLR(DE3) thus also lacks *pncC* (encoding nicotinamide mononucleotide deamidase, a key enzyme of the pyridine nucleotide cycle \[[@B7]\]) and *mtlB* (encoding a lytic murein transglycosylase). Downstream of Tn*10*, a large region (approx. 75 kb; *srlR*-*queE*) diverges significantly from BL21(DE3), with 577 nucleotide substitutions (1 to 3 bp), short insertions/deletions (1 bp), and the replacement of an IS*186* element with a full clustered regularly interspaced short palindromic repeat (CRISPR) locus, as found in *E. coli* MG1655. We infer that the entire \~85-kb region from *recA* to *queE* was transferred from the original K-12 background bearing the Δ(*srl*-*recA*)306::Tn*10* mutation. This region contains several genes involved in metabolism and other key processes, such as DNA mismatch repair (*mutS*) or stress response (*rpoS*). Importantly, *rpoS* carries a nonsense mutation at codon 33, which has been shown to reduce σ^S^ activity ([@B8]). Outside the DE3 and *recA* loci, BLR(DE3) and BL21(DE3) contain fewer than 20 differences. Of note, these include a previously identified mutation in *ilvA*, a gene responsible for isoleucine auxotrophy ([@B9]).

Globally, the genome sequence of BLR(DE3) indicates that it cannot be merely considered a *recA*-deficient BL21(DE3) strain. The newly identified differences might contribute to a differential physiology of BLR(DE3), besides its reported impaired homologous recombination.
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The complete genome sequence of *Escherichia coli* BLR(DE3) has been deposited at GenBank under accession number [CP020368](https://www.ncbi.nlm.nih.gov/nuccore/CP020368).
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